Jacques H Grosset Selected Research

Infections

4/2015	Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.
9/2013	Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice.
7/2013	Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
3/2013	Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.
1/2013	Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.
11/2012	Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
8/2012	Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
7/2011	Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models.
4/2011	Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections.
3/2011	BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacques H Grosset Research Topics

Disease

37	Tuberculosis (Tuberculoses) 01/2019 - 07/2003
18	Infections 04/2015 - 07/2003
11	Buruli Ulcer 01/2019 - 07/2010
5	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 01/2018 - 08/2006
4	Body Weight (Weight, Body) 01/2019 - 07/2012
3	Latent Tuberculosis 12/2009 - 06/2004
2	Leprosy (Hansen's Disease) 01/2017 - 01/2015
2	Pulmonary Tuberculosis 07/2013 - 08/2009
2	Granuloma 08/2012 - 07/2011
1	Hearing Loss (Hearing Impairment) 01/2015
1	Neglected Diseases 01/2014
1	Ulcer 01/2013
1	Skin Diseases (Skin Disease) 10/2011
1	Cicatrix (Scar) 03/2011
1	Emerging Communicable Diseases (Emerging Infectious Diseases) 07/2010
1	Hypoxia (Hypoxemia) 03/2009
1	Latent Infection 06/2004

Drug/Important Bio-Agent (IBA)

19	Pharmaceutical PreparationsIBA 01/2019 - 06/2004
14	Rifampin (Rifampicin)FDA LinkGeneric 01/2019 - 02/2004
14	Pyrazinamide FDA LinkGeneric 05/2014 - 02/2004
13	Moxifloxacin (Avelox)FDA Link 04/2015 - 02/2004
11	Isoniazid (Ftivazide)FDA LinkGeneric 08/2012 - 02/2004
10	rifapentine (Priftin)FDA Link 01/2019 - 12/2005
9	Clofazimine (Lamprene)FDA Link 01/2019 - 09/2013
7	AerosolsIBA 07/2013 - 03/2009
6	RifamycinsIBA 01/2019 - 07/2006
6	Streptomycin (Streptomycin Sulfate)FDA Link 01/2019 - 10/2010
6	Anti-Bacterial Agents (Antibiotics)IBA 06/2015 - 04/2011
4	FluoroquinolonesIBA 07/2013 - 07/2003
3	Drug CombinationsIBA 04/2015 - 04/2011
3	Ethambutol (Myambutol)FDA LinkGeneric 09/2013 - 12/2005
3	pretomanidIBA 01/2011 - 08/2006
2	Clarithromycin (Biaxin)FDA LinkGeneric 01/2019 - 04/2015
2	Oxazolidinones (2 Oxazolidone)IBA 01/2019 - 08/2009
2	Linezolid (Zyvox)FDA Link 01/2019 - 08/2009
2	Amikacin (A.M.K)FDA LinkGeneric 09/2013 - 03/2013
2	VaccinesIBA 01/2013 - 06/2004
2	mycolactoneIBA 01/2013 - 01/2013
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	DNA-Directed DNA Polymerase (Polymerases, DNA)IBA 06/2015
1	EnzymesIBA 05/2014
1	ProdrugsIBA 05/2014
1	AcidsIBA 01/2014
1	Levofloxacin (Levaquin)FDA Link 07/2013
1	bedaquiline (R207910)IBA 07/2013
1	trichostatin A (A 300)IBA 11/2012
1	7- (7- amino- 7- methyl- 5- azaspiro(2.4)heptan- 5- yl)- 6- fluoro- 1- (2- fluoro- 1- cyclopropyl)- 1,4- dihydro- 8- methoxy- 4- oxo- 3- quinolinecarboxylic acidIBA 04/2011
1	CytokinesIBA 03/2011
1	NitroimidazolesIBA 01/2011
1	Biomarkers (Surrogate Marker)IBA 01/2011
1	PNU-100480IBA 08/2009
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2009
1	Dioctyl Sulfosuccinic Acid (DOSS)IBA 03/2009
1	DNA VaccinesIBA 12/2005
1	Ethionamide (Trecator-SC)FDA Link 12/2005
1	DNA (Deoxyribonucleic Acid)IBA 12/2005
1	Tuberculin (PPD)IBA 06/2004

Therapy/Procedure

10	Therapeutics 01/2019 - 07/2003
7	Duration of Therapy 08/2012 - 02/2004
6	Drug Therapy (Chemotherapy) 01/2017 - 02/2004
2	Aftercare (After-Treatment) 01/2016 - 01/2013
2	Skin Transplantation (Skin Grafting) 01/2015 - 10/2011
2	Intramuscular Injections 01/2015 - 10/2010
1	Combination Drug Therapy (Combination Chemotherapy) 08/2006